Literature DB >> 32843459

Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma.

Shakthi Bhaskar1, Brooj Abro2, Tyler J Fraum3, Neha Mehta-Shah4.   

Abstract

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is known to be a rare and aggressive form of lymphoma that relapses quickly after both conventional chemotherapy and more targeted therapy. Lenalidomide is an immunomodulator that has shown safety and efficacy in multiple myeloma and is also approved for use in several types of lymphoma. In the case described here, the patient had a significant partial response to lenalidomide, which has not previously been described in this type of lymphoma. Given how aggressive and difficult to treat ALK+ LBCL is, further research is warranted to more completely elucidate the mechanism of action of lenalidomide in ALK+ LBCL and its role in treatment. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; therapeutic indications

Mesh：

Substances：

Year:  2020        PMID： 32843459      PMCID： PMC7449333          DOI： 10.1136/bcr-2020-235578

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  17 in total

1.  Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

Authors:  Francisco J Hernandez-Ilizaliturri; George Deeb; Pier L Zinzani; Stefano A Pileri; Farhana Malik; William R Macon; Andre Goy; Thomas E Witzig; Myron S Czuczman
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

2.  Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.

Authors:  Maxi Wass; Timo Behlendorf; Bärbel Schädlich; Anja Mottok; Andreas Rosenwald; Hans-Joachim Schmoll; Karin Jordan
Journal:  Eur J Haematol       Date:  2014-01-10       Impact factor: 2.997

Review 3.  ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature.

Authors:  Zenggang Pan; Shimin Hu; Min Li; Yi Zhou; Young S Kim; Vishnu Reddy; Jennifer N Sanmann; Lynette M Smith; Mingyi Chen; Zifen Gao; Huan-You Wang; Ji Yuan
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

4.  Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.

Authors:  Athena Kritharis; Michael Coyle; Jaya Sharma; Andrew M Evens
Journal:  Blood       Date:  2015-03-03       Impact factor: 22.113

5.  The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Martha Q Lacy; Steven R Zeldenrust; Suzanne R Hayman; Shaji K Kumar; Susan M Geyer; John A Lust; Jacob B Allred; Thomas E Witzig; S Vincent Rajkumar; Philip R Greipp; Stephen J Russell; Brian Kabat; Morie A Gertz
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

6.  Lenalidomide is safe and active in Waldenström macroglobulinemia.

Authors:  Guillemette Fouquet; Stéphanie Guidez; Marie-Odile Petillon; Chanaz Louni; Bella Ohyba; Malek Dib; Stéphanie Poulain; Charles Herbaux; Audrey Martin; Béatrice Thielemans; Pauline Brice; Sylvain Choquet; Jana Bakala; Claire Bories; Hélène Demarquette; Morgane Nudel; Olivier Tournilhac; Bertrand Arnulf; Steven LeGouill; Pierre Morel; Anne Banos; Lionel Karlin; Gilles Salles; Véronique Leblond; Xavier Leleu
Journal:  Am J Hematol       Date:  2015-10-06       Impact factor: 10.047

7.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Meletios Dimopoulos; Andrew Spencer; Michael Attal; H Miles Prince; Jean-Luc Harousseau; Anna Dmoszynska; Jesus San Miguel; Andrzej Hellmann; Thierry Facon; Robin Foà; Alessandro Corso; Zvenyslava Masliak; Marta Olesnyckyj; Zhinuan Yu; John Patin; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

8.  Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.

Authors:  Michinori Ogura; Yoshitaka Imaizumi; Naokuni Uike; Norio Asou; Atae Utsunomiya; Toshiki Uchida; Tomohiro Aoki; Kunihiro Tsukasaki; Jun Taguchi; Ilseung Choi; Dai Maruyama; Kisato Nosaka; Nianhang Chen; Shuichi Midorikawa; Tomoko Ohtsu; Kensei Tobinai
Journal:  Lancet Haematol       Date:  2016-02-12       Impact factor: 18.959

Review 9.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature.

Authors:  Xiang-Nan Jiang; Bao-Hua Yu; Wei-Ge Wang; Xiao-Yan Zhou; Xiao-Qiu Li
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

10.  Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.

Authors:  Christine Chen; Donna E Reece; David Siegel; Ruben Niesvizky; Ralph V Boccia; Edward A Stadtmauer; Rafat Abonour; Paul Richardson; Jeffrey Matous; Shaji Kumar; Nizar J Bahlis; Melissa Alsina; Robert Vescio; Steven E Coutre; Dennis Pietronigro; Robert D Knight; Jerome B Zeldis; Vincent Rajkumar
Journal:  Br J Haematol       Date:  2009-05-26       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.